Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The firm, which says PTC Therapeutics is a top pick in 2025, says the revenue beat for 2024 was “significant” and helps to show the strength of the base business — regardless of the ultimate fate of Translarna in EU — as the pipeline continues to move forward, the analyst tells investors in a research note. The focus remains on the phenylketonuria and Huntington’s disease programs, and Cantor sees more than 50% upside alone for the current risk-adjusted opportunity in PKU and HD. The firm continues to believe PTC has the best asset in the business for Huntington’s disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Surpasses Revenue Guidance for 2024
- PTC Therapeutics provides potential key clinical, regulatory events in 2025
- PTC Therapeutics sees FY25 revenue $600M-$800M
- PTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31M
- PTC Therapeutics sees FY24 revenue ~$814M, consensus $795.38M